Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury-Reference-Cited by-同舟云学术

Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury

Published:2019-04 Issue:8 Volume:29 Page:995-1000
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Goncalves Maria B.,Clarke Earl,Jarvis Christopher I.,Barret Kalindjian S.,Pitcher Thomas,Grist John,Hobbs Carl,Carlstedt Thomas,Jack Julian,Brown Jane T.,Mills Mark,Mumford Peter,Borthwick Alan D.,Corcoran Jonathan P.T.

Funder

MRC

Wellcome Trust

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference12 articles.

1. Retinoids in neural development;Maden,1999

2. The role of retinoic acid receptors in neurite outgrowth from different populations of embryonic mouse dorsal root ganglia;Corcoran;J Cell Sci,2000

3. A retinoic acid receptor β agonist (CD2019) overcomes inhibition of axonal outgrowth via phosphoinositide 3-kinase signalling in the injured adult spinal cord;Agudo;Neurobiol Dis,2010

4. Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist;Clarke;Bioorg Med Chem,2018

5. Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity;Kagechika;J Med Chem,1988

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. C286, an orally available retinoic acid receptor β agonist drug, regulates multiple pathways to achieve spinal cord injury repair;Frontiers in Molecular Neuroscience;2024-08-20

2. Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL‐286, a novel retinoic acid receptor‐β agonist for treatment of spinal cord injury, in male healthy participants;British Journal of Clinical Pharmacology;2023-08-09

3. Recent advances in the design of RAR α and RAR β agonists as orally bioavailable drugs. A review;Bioorganic & Medicinal Chemistry;2020-10

4. RARβ Agonist Drug (C286) Demonstrates Efficacy in a Pre-clinical Neuropathic Pain Model Restoring Multiple Pathways via DNA Repair Mechanisms;iScience;2019-10

5. Corrigendum to “Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury” [Bioorg. Med. Chem. Lett. 29(8) (2019) 995–1000];Bioorganic & Medicinal Chemistry Letters;2019-08